Status:

COMPLETED

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Lead Sponsor:

Andrei Iagaru

Collaborating Sponsors:

General Electric

Conditions:

Breast Carcinoma

Estrogen Receptor Positive

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.

Detailed Description

PRIMARY OBJECTIVES: I. To evaluate the feasibility of 68-Ga RM2 PET/MRI for identification of estrogen receptor positive primary breast cancer and metastases OUTLINE: Patients receive 68-Ga-RM2 int...

Eligibility Criteria

Inclusion

  • ER+ breast cancer at initial diagnosis prior to surgery or at recurrence (at least one ER+ lesion based on results of biopsy).
  • Able to provide written consent
  • Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent)

Exclusion

  • Less than 18 years-old at the time of radiotracer administration
  • Inability to lie still for the entire imaging time
  • Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
  • Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
  • Renal function impairment preventing administration of MRI contrast
  • Metallic implants (contraindicated for MRI)

Key Trial Info

Start Date :

March 19 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 15 2021

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT03831711

Start Date

March 19 2019

End Date

November 15 2021

Last Update

December 13 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Stanford Cancer Institute Palo Alto

Palo Alto, California, United States, 94304